Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
US Department of Justice
Merck
Colorcon
Covington
Baxter
Harvard Business School
Queensland Health

Generated: December 12, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,566,276

« Back to Dashboard

Title:Phthalazinone derivatives
Abstract: Compounds of the formula (I): ##STR00001## wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NR.sup.X or CR.sup.XR.sup.Y; if X.dbd.NR.sup.X then n is 1 or 2 and if X.dbd.CR.sup.XR.sup.Y then n is 1; R.sup.X is selected from the group consisting of H, optionally substituted C.sub.1-20 alkyl, C.sub.5-20 aryl, C.sub.3-20heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R.sup.Y is selected from H, hydroxy, amino; or R.sup.X and R.sup.Y may together form a spiro-C.sub.3-7 cycloalkyl or heterocyclyl group; R.sup.C1and R.sup.C2 are both hydrogen, or when X is CR.sup.XR.sup.Y, R.sup.C1, R.sup.C2, R.sup.X and R.sup.Y, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R.sup.1 is selected from H and halo.
Inventor(s): Martin; Niall Morrison Barr (Cambridge, GB), Smith; Graeme Cameron (Cambridge, GB), Jackson; Stephen Philip (Cambridge, GB), Loh; Vincent Junior M (Horsham, GB), Cockcroft; Xiao-Ling Fan (Horsham, GB), Matthews; Ian Timothy Williams (Horsham, GB), Menear; Keith Allan (Horsham, GB), Kerrigan; Frank (Cornwall, GB), Ashworth; Alan (London, GB)
Assignee: KUDOS PHARMACEUTICALS LIMITED (Cambridge, Cambridgeshire, GB)
Filing Date:Sep 14, 2015
Application Number:14/853,360
Claims:1. A method of treatment for pancreatic cancer deficient in a HR dependent DNA DSB repair pathway comprising administering to a subject a therapeutically effective amount of a compound of formula (Ib): ##STR00440## or an isomer or salt thereof, or a mixture of any thereof, wherein: A and B together represent a fused aromatic ring, optionally substituted with one or more substituent groups selected from halo, nitro, hydroxyl, ether, thiol, thioether, amino, C.sub.1-7 alkyl, C.sub.5-1 aryl and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur; R.sup.x is selected from H, C.sub.1-7 alkyl, C.sub.5-7 aryl, amido, thioamido, ester, acyl, and sulfonyl groups and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur, wherein the acyl, C.sub.1-7 alkyl, C.sub.5-7 aryl or heterocyclyl group is optionally substituted with one or more substituent groups selected from C.sub.1-7 alkyl, C.sub.5-7 aryl, halo, hydroxyl, ether, nitro, cyano, acyl, carboxy, ester, amido, amino, acylamido, ureido, acyloxy, thiol, thioether, sulfoxide, sulfonyl, thioamido, sulfonamido and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur; R.sup.C1and R.sup.C2 are both hydrogen; and R.sup.1 is selected from H and halo; wherein the cancer is pancreatic cancer; and wherein the cancer comprises one or more cancer cells having a reduced or abrogated ability to repair DNA DSB by HR relative to normal cells.

2. The method of claim 1, wherein the fused aromatic ring represented by A and B together is benzene.

3. The method of claim 1, wherein R.sup.1 is selected from H, CI, and F.

4. The method of claim 1, wherein R.sup.x is selected from H, C.sub.1-7 alkyl, C.sub.5-7 aryl, acyl, sulfonyl, amido, and thioamido groups, wherein the acyl, C.sub.1-7 alkyl or C.sub.5-7 aryl group is optionally substituted with one or more substituent groups selected from C.sub.1-7 alkyl, C.sub.5-7 aryl, halo, hydroxyl, ether, nitro, cyano, acyl, carboxy, ester, amido, amino, acylamido, ureido, acyloxy, thiol, thioether, sulfoxide, sulfonyl, thioamido, sulfonamido and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur.

5. The method of claim 1, wherein the compound of formula (Ib) or an isomer or salt thereof, or a mixture of any thereof, is a compound of formula (II): ##STR00441## or an isomer or salt thereof, or a mixture of any thereof, wherein: R.sup.C3 is selected from C.sub.1-7 alkyl, C.sub.5-7 aryl, and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur, wherein the C.sub.1-7 alkyl, C.sub.5-7 aryl or heterocyclyl group is optionally substituted with one or more substituent groups selected from C.sub.1-7 alkyl, C.sub.5-7 aryl, halo, hydroxyl, ether, nitro, cyano, acyl, carboxy, ester, amido, amino, acylamido, ureido, acyloxy, thiol, thioether, sulfoxide, sulfonyl, thioamido, sulfonamido and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur.

6. The method of claim 1, wherein the compound of formula (Ib) or an isomer or salt thereof, or a mixture of any thereof, is a compound of formula (Ill): ##STR00442## or an isomer or salt thereof, or a mixture of any thereof, wherein R is selected from: ##STR00443##

7. The method of claim 1, wherein the compound of formula (Ib) or an isomer or salt thereof, or a mixture of any thereof, is a compound of formula (IV), ##STR00444## or an isomer or salt thereof, or a mixture of any thereof.

8. The method of claim 1, further comprising identifying the subject as having a cancer condition that is deficient in a HR dependent DNA DSB repair pathway.

9. The method of claim 1, further comprising administering ionizing radiation, a chemotherapeutic agent, or a combination thereof to the subject.

10. The method of claim 1, wherein the one or more cancer cells has a BRCA1 or BRCA2 deficient phenotype.

11. The method of claim 10, wherein the one or more cancer cells are deficient in BRCA1 or BRCA2.

12. The method of claim 1, wherein the subject is heterozygous for a mutation in a gene encoding a component of the HR dependent DNA DSB repair pathway.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Cerilliant
Citi
Fish and Richardson
Merck
US Department of Justice
Federal Trade Commission
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.